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Abstract
Background: The five-year survival rates for head and neck squamous cell carcinoma (HNSCC) patients are less
than 50%, and the prognosis has not improved, despite advancements in standard multi-modality therapies. Hence
major emphasis is being laid on identification of novel molecular targets and development of multi-targeted
therapies. 14-3-3 zeta, a multifunctional phospho-serine/phospho-threonine binding protein, is emerging as an
effector of pro-survival signaling by binding to several proteins involved in apoptosis (Bad, FKHRL1 and ASK1) and
may serve as an appropriate target for head and neck cancer therapy. Herein, we determined effect of
guggulsterone (GS), a farnesoid X receptor antagonist, on 14-3-3 zeta associated molecular pathways for
abrogation of apoptosis in head and neck cancer cells.
Methods: Head and neck cancer cells were treated with guggulsterone (GS). Effect of GS-treatment was evaluated
using cell viability (MTT) assay and apoptosis was verified by annexin V, DNA fragmentation and M30 CytoDeath
antibody assay. Mechanism of GS-induced apoptosis was determined by western blotting and co-IP assays using
specific antibodies.
Results: Using in vitro models of head and neck cancer, we showed 14-3-3 zeta as a key player regulating
apoptosis in GS treated SCC4 cells. Treatment with GS releases BAD from the inhibitory action of 14-3-3 zeta in
proliferating HNSCC cells by activating protein phosphatase 2A (PP2A). These events initiate the intrinsic
mitochondrial pathway of apoptosis, as revealed by increased levels of cytochrome c in cytoplasmic extracts of GS-
treated SCC4 cells. In addition, GS treatment significantly reduced the expression of anti-apoptotic proteins, Bcl-2,
xIAP, Mcl1, survivin, cyclin D1 and c-myc, thus committing cells to apoptosis. These events were followed by
activation of caspase 9, caspase 8 and caspase 3 leading to cleavage of its downstream target, poly-ADP-ribose
phosphate (PARP).
Conclusion: GS targets 14-3-3 zeta associated cellular pathways for reducing proliferation and inducing apoptosis
in head and neck cancer cells, warranting its investigation for use in treatment of head and neck cancer.
Background
Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer in the U.S. and the
fourth most prevalent cancer in men worldwide,
accounting for over 500,000 new cases annually [1]. The
5-year survival rate is less than 50%, and the prognosis
of advanced cases has not improved much over the past
three decades [2,3]. Despite standard multi-modality
therapeutic interventions, including surgery, radiation
and/or chemo-radiotherapy, head and neck cancer
patients have a substantial risk of developing second pri-
mary tumors, often attributed to “field cancerization” -
molecular alterations arising due to chronic carcinogen
exposure of the upper aerodigestive tract [4-6]. More-
over, the limited efficacy, lack of safety, and high cost of
mono-targeted therapies including EGFR inhibitors,
limit their use in head and neck cancer management
[7-9]. Hence major emphasis is being laid on identifica-
tion of novel molecular targets and development of
multi-targeted therapies. Clinical development of agents
that can delay onset and/or progression could signifi-
cantly improve the management of head and neck
cancer.
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16-dione], obtained from the plant Commiphora mukkul
is used for treatment of obesity, hyperlipidemia, athero-
sclerosis, diabetes and osteoarthritis [10-12]. Besides, GS
has also been reported to induce apoptosis, suppress
proliferation, invasion, angiogenesis and metastasis in a
wide variety of human cancer cell lines, including acute
myeloid leukemia, head and neck, prostate, lung, breast,
colon and ovarian cancer [13-22]. Interestingly, normal
human fibroblasts, non-transformed prostate and colon
epithelial cell lines are relatively resistant to growth inhi-
bition by GS in comparison to cancer cells [13,16,18].
Various mechanisms have been proposed to explain the
anti-carcinogenic effects of GS, including inhibition of
reactive oxygen species (ROS), suppression of inflamma-
tion and inhibition of nuclear receptors (farnesoid X
receptors), transcription factors [nuclear factor kappa B
(NFB), signal transducer and activator of transcription
3 (STAT3)], anti-apoptotic (Bcl-2, Bax, Bad and xIAP)
and cell cycle-regulatory proteins (p21, p16 and cyclin
D1). In addition, Leeman-Neill et al., [23] recently
showed GS-treatment decreased the expression of both
pSTAT3 (p-tyr-705), total STAT3 and hypoxia-inducible
factor (HIF)-1a in HNSCC cell lines and in a xenograft
model of HNSCC. Similarly, in our earlier reports, we
also demonstrated GS reduced the levels of pSTAT3
(p-tyr-705) in both multiple myeloma and HNSCC cell
lines [24].
14-3-3 family of proteins consists of seven members
(ζ, s, b, h, θ, g and ε) which are multifunctional phos-
pho-serine/phospho-threonine binding molecules that
can serve as effectors of survival signaling [25].
Recently, using quantitative proteomics screens we
identified a panel of proteins including 14-3-3 zeta, as
biomarkers for diagnosis and prognosis of head and
neck cancer with a high sensitivity and specificity
[25-29] and suggested their involvement in develop-
ment and progression of head and neck cancer. An
emerging role for 14-3-3 zeta as an effectors of pro-
survival signaling is suggested in part by the large
number of 14-3-3 binding proteins involved in apopto-
sis, such as A20, ASK1, FKHRL1 and Bad [25,30-35].
In addition, using in vitro models of head and neck
cancer, we also showed knocking down expression of
14-3-3 zeta sensitizes head and neck cancer cells to
chemotherapy [36], revealing its therapeutic potential.
In the current study, we investigated the effect of GS
on 14-3-3 zeta and its role in GS-induced apoptosis in
HNSCC cells. Our results demonstrated GS-induces
apoptosis by intrinsic mitochondrial pathway by a pro-
tein phosphatase mediated dephosphorylation of Bad,
thus releasing it from inhibitory action of 14-3-3 zeta,
which sequesters it in cytoplasm of proliferating cells.
Methods
Antibodies and Reagents
Z-guggulsterone (GS), 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT), propidium
iodide (PI) were purchased from Sigma (St. Louis, MO).
For details of the antibodies used in this study, see
Additional file 1: Supplementary Table S1. Caspase-3
activity assay kit was obtained from R&D systems (Min-
neapolis, MN); Caspase-9 and Caspase-8 activity assay
kit from Genentech (South San Francisco, CA). Protein
A-sepharose beads were obtained from GE Healthcare
Biosciences, (Uppsala, Sweden).
Cell culture
Human head and neck squamous carcinoma cell lines,
SCC4 was obtained from American Type Culture Col-
lection (ATCC) and HSC2 (JCRB0622) was obtained
from Health Science Research Resources Bank (HSRRB),
Japan, were grown in monolayer cultures in Dulbecco’s
modified eagle medium (DMEM) (Sigma, St. Louis,
MO) supplemented with 10% fetal bovine serum (FBS)
(Sigma), 1 mM L-glutamine, 1 mM minimum essential
medium (MEM), 100 μg/ml streptomycin and 100 U/ml
penicillin in a humidified incubator (5% carbon-dioxide,
95% air) at 37°C as described earlier [36]. For the assays
described below, unless specified, head and neck cancer
cells were cultured in 100 mm culture dishes for 24 h,
followed by treatment with GS (50 μM) in DMEM only
(without FBS) or medium containing DMSO (< 0.05%)
which served as a vehicle control.
Cell viability assay
Head and neck cancer cells (5 × 10
3/well) were plated in
a 96-well plate for 24 hrs. Cells were incubated in tripli-
cates in the presence of medium containing GS (0 - 100
μM) or 0.02% of DMSO which served as a vehicle con-
trol in a final volume of 100 μlf o r2 4-7 2h r sa t3 7 ° C .
Cell death was measured by adding 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) at 37°
C for 3-4 h. The formazan crystals were dissolved in
100 μl of dimethylsulphoxide (DMSO) and optical den-
sity (OD) was measured at wavelength of 570 nm. The
percentage cell death was calculated individually for
each dose as follows: (ODcontrol -O D treated/ODcontrol)×
100. The percentage cell viability was calculated as [% of
viable cells = (100 - % cell death)] [36].
Cell cycle analysis using flow cytometry
GS-treated and untreated, control SCC4 cells collected
a t2 4ha n d4 8hw e r ew a s h e dw i t hp h o s p h a t eb u f f e r
saline (PBS, pH = 7.4). The cells were fixed in 70% etha-
nol for 30 min at -20°C and resuspended in buffer con-
taining PBS-EDTA (0.5 M, pH = 8.0), Triton X-100
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100 μg/ml) for flow cytometry analysis. The PI-labeled
cells were analyzed using a BD Canto flow cytometer
and the output thus obtained was analyzed using the
BD FACS Diva software (BD Biosciences, CA) [36].
Annexin V assay
Annexin V and propidium iodide double staining was
used to quantify apoptosis. Control and GS-treated
SCC4 cells were harvested at 24 h and 48 h, washed
with ice-cold PBS (pH = 7.4), resuspended in cold cal-
cium binding medium (10 mM HEPES, pH 7.4, 140
mM NaCl and 2.5 mM CaCl2), and stained with FITC-
labeled annexin V and propidium iodide, following man-
ufacturer’s protocol (R&D Systems,M i n n e a p o l i s ,M N ) .
Following incubation at room temperature for 15 min in
the dark, cells were analyzed with FACS CantoTM flow
cytometer (BD Biosciences, San Jose, CA) [36].
DNA fragmentation assay
SCC4 cells (2 × 10
6) were treated with GS for different
time intervals; harvested, resuspended in 200 μlo fi c e
cold lysis buffer containing 10 mM Tris-HCl (pH = 7.4),
150 mM NaCl, 5 mM EDTA and 0.5% Triton X-100
and incubated for 30 min. Lysates were vortexed and
cleared by centrifugation at 10,000 g for 20 min. Frag-
mented DNA in the supernatant was extracted with an
equal volume of neutral phenol: choloroform: isoamyl
alcohol (25:24:1, vol/vol/vol) and analyzed electrophore-
tically on 1.5% agarose gel containing ethidium bromide
after measuring the DNA content using UV-
spectrophotometer.
M30 CytoDeath Antibody Assay
The M30 CytoDeath antibody binds to a caspase-cleaved
formalin resistant epitope of cytokeratin 18, which is
exposed during early apoptosis. Expression and localiza-
tion of M30 protein was observed in GS treated and
untreated control SCC4 cells using confocal laser scan
microscopy as described by earlier [37]. Briefly, GS treated
and control SCC4 cells grown over coverslip, were fixed in
methanol for 20 min at -20°C, rinsed with PBS (pH = 7.2)
and incubated with M30 CytoDeath antibody overnight at
4°C. After rinsing in PBS, the coverslips were incubated
with biotinylated secondary antibody (LSAB plus Kit,
DAKO Cytomations, Denmark) for 45 min at 37°C fol-
lowed by incubation with streptavidin-conjugated fluoro-
chrome, fluorescein isothiocyanate (FITC) (DAKO
Cytomations, Glostrup, Denmark). Thereafter, the cover-
slips were counterstained with propidium iodide (PI, 10
mg/ml; Sigma, MO) for 30 sec. Coverslips were rinsed,
mounted with antifade agent and examined using a confo-
cal laser scanning microscope (CLSM)-LSM510 scanning
module (Carl Zeiss Microscopy, Jena GmbH, Germany).
Co-immunoprecipitation (co-IP) assays
Co-immunoprecipitation (co-IP) assays were carried out
using specific antibodies and analyzed by western blot-
ting. Briefly, head and neck cancer cells (SCC4) were
rinsed in ice-cold PBS and lysed in IP lysis buffer [37].
Lysates were incubated on ice for 30 min. and cell deb-
ris was removed by centrifugation. Lysates were pre-
cleared by adding 20 μl of Protein A Sepharose (GE
Healthcare Biosciences, Uppsala, Sweden), followed by
overnight incubation with specific antibodies (polyclonal
anti-14-3-3zeta/anti-Bax or monoclonal anti-Bad/anti-
Bcl2/anti-Bcl-xL antibody) on a rocker at 4°C. Immuno-
complexes were pulled down by incubating with Protein
A-Sepharose for 2 h at 4°C, followed by washing with
4X ice-cold lysis buffer to eliminate non-specific interac-
tions [37]. Protein A-sepharose-bound immunocom-
plexes were then resuspended in Laemelli sample buffer,
boiled for 5 min. and analyzed by Western blotting
using specific antibodies as described below.
Western blotting (WB)
Whole-cell lysates were prepared from GS-treated SCC4
cells and protein concentration was determined using
the Bradford reagent (Sigma) and equal amounts of pro-
teins (60 μg/lane) were resolved on 12% sodium dodecyl
sulfate (SDS)-polyacrylamide gel [37]. The proteins were
then electro-transferred onto polyvinylidene fluoride
(PVDF) membrane. After blocking with 5% non-fat milk
in Tris-buffered saline (TBS, 0.1 M, pH = 7.4), blots
were incubated with specific antibodies as per manufac-
turer’s recommended protocol at 4°C overnight. Protein
abundance of a-tubulin (Santa Cruz Biotechnology, CA)
served as a control for protein loading in each lane.
Membranes were incubated with HRP-conjugated
secondary antibodies, (DAKO Cytomation, Glostrup,
Denmark), diluted at an appropriate dilution in 1% BSA,
for 2 h at room temperature. After each step, blots were
washed three times with Tween (0.1%)-Tris-buffer saline
(TTBS). Protein bands were detected by the enhanced
chemiluminescence method (ECL), Santa Cruz Biotech-
nology (Santa Cruz, CA) on XO-MAT film.
Cytochrome c release Assay
SCC4 cells (2 × 10
5/well) were cultured in 6-well plates
for 24 h followed by treatment with GS washed with ice
- cold PBS (pH = 7.2) and resuspended in isotonic mito-
chondrial buffer (210 mM mannitol, 70 mM sucrose, 1
m ME G T A ,1 0m MH e p e s ,p H7 . 5 ,0 . 1 %B S A )c o n t a i n -
ing protease inhibitor cocktail. The resuspended cells
were homogenized with a polytron homogenizer and
then centrifuged at 2000 g for 3 min to pellet the nuclei
and unbroken cells. The supernatant was centrifuged at
13,000 g for 10 min to pellet mitochondria [38]. The
supernatant was further centrifuged at 15,000 g to pellet
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the cytosolic fractions. The mitochondrial fraction was
washed with mitochondrial buffer twice, resuspended
with 1% Non-Idet P-40 lysis buffer, mixed for 60 min,
and then centrifuged at 13,000 g for 10 min at 4°C. The
supernatant containing mitochondrial proteins was col-
lected and each sub-cellular fraction was subjected to
Western blotting as described above.
Caspase activity assay
Briefly, SCC4 cells (1 × 10
6) were treated with GS for 0,
6, 12, 24 and 36 h at 37°C. The caspase enzyme activity
in the cell lysates (treated and control) was measured by
direct assay using synthetic fluorogenic substrate (Ac-
D E V D - A F C ,s u b s t r a t ef o rc a s p a s e3( R & DS y s t e m s )a n d
Ac-LEHD-AFC, substrate for caspase 8 and caspase 9.
The amount of fluorogenic 7-amino-4-methyl coumarin
(AMC)/7-amino-4-trifluoromethyl coumarin (AFC) moi-
ety released was measured using a spectofluorimeter.
CD95/Fas assay
Briefly, SCC4 cells (1 × 10
6) were treated with GS for 0,
6, 12, 24 and 36 h at 37°C. Cells were harvested, washed
with PBS and incubated with FITC-conjugated antibody
against CD95 (Fas) for 1 h at 4°C. After incubation, cells
were washed, suspended in PBS containing 0.05% (w/v)
sodium azide and analyzed using BD Canto flow cyt-
ometer and data were analyzed using the BD FACS Diva
software. The gates were set to exclude dead cells and
10,000 cells were analyzed. Data are displayed as percen-
tage of cells showing CD95 positivity.
Statistical Analysis
Statistical analysis was carried out using SPSS 10.0 soft-
ware (Chicago). Statistical significance was determined
using the paired, two-tailed Student’st - t e s t .p≤ 0.05
was considered to be significant. Each assay was
repeated at least 3 times (unless otherwise specified), to
check the validity of the results obtained. The mean
values ± standard deviations (S.D.) are presented in
figures.
Results
GS inhibits cell proliferation and induces cell death
To determine the cytotoxic effect of GS, head and neck
cancer cells (SCC4/HSC2) were treated with varying
concentrations (5 - 100 μM) for 24 h - 72 h. MTT assay
revealed dose and time dependent increased cytotoxicity
of GS in head and neck cancer cells (SCC4 and HSC2)
as shown in Figure 1a and 1b respectively. Treatment of
SCC4 cells with GS produced a cytotoxic effect with an
inhibitory concentration at 50% (IC50)o f5 0μMa n d7 5
μM in SCC4 and HSC2 cells respectively. Therefore, 50
μM GS was used for all subsequent experiments in
SCC4 cells. Flow cytometry analysis using propidium
iodide staining showed significant increase in sub-G0
fraction of cell cycle in 24 h - 48 h indicating cell death
in GS (50 μM) - treated SCC4 cells in comparison with
untreated control cells (Figure 2A). Interestingly, GS-
treated SCC4 cells also showed marked differences in
G2/M fraction of cell cycle in comparison to untreated
controls, as revealed by flow cytometry analysis (Figure
2A(iv).
GS treatment induces apoptosis in head and
neck cancer cells
Annexin V assay was carried out to evaluate GS induced
apoptosis in head and neck cancer cells. GS treated
SCC4 cells showed significant increase in apoptosis
(40%) as early as in 24 h (Figure 2B). These results were
further confirmed using M30 cyto-death and DNA frag-
mentation assay. Increased cytoplasmic expression of
M30 protein and DNA fragmentation that are character-
istics of apoptosis were observed in GS - treated SCC4
cells in 48 h (Figure 2C &2D). However, no detectable
immunostaining was observed by M30-cytodeath assay
in the control cells treated with vehicle alone, confirm-
ing induction of apoptosis by GS treatment (Figure 2C).
Figure 1 GS reduces cell viability of HNSCC cell lines.C e l l
viability was determined in SCC4 and HSC2 cells after 24 h - 72 h
of incubation with 5, 10, 20, 50, 75 and 100 μM GS. Viable cell
number was assayed by MTT uptake. Graphs show % of viable (a)
SCC4 and (b) HSC2 cells on treatment with GS in a dose- and time-
dependent manner. Each data point represents the mean ±
standard deviation (S.D.) of 3 independent experiments.
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Page 4 of 12Figure 2 GS induces cell death in HNSCC cells.( A) SCC4 cells treated with 50 μMG Sf o r0h ,2 4h ,a n d4 8hw e r ef i x e da n ds t a i n e dw i t h
propidium iodide and cell cycle analysis was carried out using flow cytometry as described in Materials and Methods. Panel shows
representative DNA histograms of GS-treated SCC4 cells in sub-G0,G 0/G1, S- and G2/M phase of cell cycle after (i) 0 h, (ii) 24 h; (iii) 48 h; (iv)
histograms showing mean % of cell population in each phase of cell cycle (* p < 0.05). (B) Annexin V assay. The panel shows % apoptotic cells
on treatment with GS (50 μM) for (i) 0 h, (ii) 24 h and (iii) 48 h and (iv) histogram showing mean % of apoptotic cells (mean ± S.D., * p < 0.005).
(C) Immunofluorescence analysis revealing M30 protein expression in SCC4 cells (i) untreated control cells; (ii) GS (50 μM) treatment for 12 h
(original magnification × 400). (D) SCC4 cells were treated with GS (50 μM) for 6 h - 48 h followed by DNA extraction as described in materials
and methods. Panel represents an agarose gel electrophoretogram showing DNA ladder confirming apoptosis.
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anti-apoptotic proteins
Treatment with GS (50 μM) decreased expression of cell
cycle regulatory protein-cyclin D1, while it induced
expression of cyclin-dependent kinase inhibitor
p21
WAF1/CIP1 and p27 in SCC4 cells in a time dependent
manner (Figure 3A(i-iii). Interestingly, GS treatment also
induced a significant shift in the Bax/Bcl2 ratio within
36 h of GS treatment in SCC4 cells (Figure 3A(iv-v, xii),
while it did not show marked effect on expression of
Bak at the indicated time points (Figure 3A(vii), suggest-
ing GS-induced apoptosis in head and neck cancer cells
involves the intrinsic mitochondrial pathway. Treatment
with GS (50 μM) suppressed the expression of anti-
apoptotic proteins xIAP, Mcl1, c-myc and survivin in
SCC4 cells (Figure 3A(viii-xi).
Cytochrome c release from mitochondria is the most
important step in the apoptosis cascade involving intrin-
sic mitochondrial pathway. As shown in Figure 3B,
we observed a significant increase in expression of
cytochrome c protein in cytosolic fractions of SCC4
cells on treatment with GS in a time dependent manner.
GS induces dissociation of Bad from 14-3-3 zeta to
activate intrinsic mitochondrial pathway
The pro-apoptotic function of Bad requires its localiza-
tion on outer mitochondrial membrane to release Bax
from Bcl2/Bcl-xl, forming ion pores, thereby increasing
membrane permeability releasing cytochrome c into
cytoplasm. However, Bad is sequestered in cytoplasm by
14-3-3 zeta in proliferating cancer cells inhibiting its
pro-apoptotic functions. Our results showed a time
dependent decrease in expression of phosphorylated-Bad
(pBad, Ser-136), while no significant change in expres-
sion of total Bad was observed on GS treatment in
SCC4 cells (Figure 4A). Using co-immunoprecipitation
(co-IP) assays, we showed that decrease in phosphoryla-
tion of Bad results in its dissociation from 14-3-3 zeta
in the cytosol, on treatment with GS (50 μM) as shown
in Figure 4B. The dephosphorylated Bad accumulates on
Figure 3 (A) GS modulates cell cycle regulatory and anti-apoptotic proteins. SCC4 cells were incubated for different time points (0 h -
36 h) with of GS (50 μM) and whole-cell extracts were prepared. Panel shows western blot analysis of (i) cyclin D1, (ii) p27, (iii) p21, (iv) Bax, (v)
Bcl2, (vi) Bak, (vii) tBid, (viii) xIAP, (ix) Mcl1, (x) c-myc and (xi) survivin (xii) a-tubulin served as a loading control, (xiii) histograms showing fold
change (mean ± S.D.) of protein expression, (xiv) histograms showing increased Bax/Bcl2 ratio (mean ± S.D.) in SCC4 cells (*
,**p < 0.005) (B)
Panel shows increased expression of cytochrome c in cytosolic fractions of GS-treated SCC4 cells in a time dependent manner (0 h - 36 h).
Absence of succinate dehydrogenase (mitochondrial protein) expression in cytosolic fractions (C) confirmed the purity of cytosolic (C) and
mitochondrial (M) sub-cellular fractions (* p < 0.05).
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Page 6 of 12Figure 4 (A) GS induces dephosphorylation of pBAD.W h o l ec e l ll y s a t e so b t a i n e df r o mG S( 5 0μM) treated SCC4 cells were subjected to
western blotting using specific antibodies for pBad, total Bad and a-tubulin. Panel shows the dephosphorylation of Bad in time-dependent
manner (0 h - 12 h) while no difference was observed in the expression of total Bad protein in GS-treated SCC4 cells. a-tubulin served as
loading control. (B) GS induces dissociation of Bad from 14-3-3ζ in head and neck cancer cells. Co-IP assays using specific antibodies were
carried out and analyzed by western blotting as described in Materials and Methods. Treatment with GS induced dissociation of Bad from 14-3-
3ζ as shown in panel (i) and (ii); association of Bad with Bcl2 as shown in panel (iii) and (iv); association of Bad with Bcl-xL (v) and (vi); and
dissociation of pro-apoptotic protein Bax from Bcl-xL (vii and viii) as well as Bcl2 (ix and x) (C) Okadaic acid (OA) inhibits GS-induced
dephosphorylation of Bad. Panel shows inhibition of dephosphorylation of Bad (Ser-136) and its dissociation from 14-3-3ζ in a time-dependent
manner as determined using co-IP assays followed by western blotting.
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with either Bcl2 or Bcl-xl releasing Bax from inhibitory
action of these anti-apoptotic proteins as revealed by
co-IP assays using specific antibodies (Figure 4B). These
results were further confirmed by reverse co-IP assays
followed by western blotting.
The dephosphorylation of Bad on Ser-136 has been
reported by protein phosphatases 2A (PP2A) in response
to various apoptotic stimulus [39]. Therefore, we evalu-
ated dephosphorylation of Bad and its dissociation from
14-3-3 zeta on GS treatment (50 μM) in presence of
serine/threonine phosphatase inhibitor, okadaic acid
(OA). Our results clearly showed no change in depho-
sphorylation of pBad on treatment with GS in presence
of okadaic acid (OA) (Figure 4C). Further, co-IP assays
showed inhibition of dissociation of pBad from 14-3-3
zeta on GS-treatment in presence of OA, thereby inhi-
biting apoptosis (Figure 4C). These results suggest that
GS recruits a phosphatase to release pro-apoptotic pro-
tein, Bad from 14-3-3 zeta activating the intrinsic mito-
chondrial pathway of apoptosis.
Caspase assay
Caspase 9 and caspase 3 assays were carried out using
fluorogenic substrates for quantitative analysis in GS-trea-
ted and untreated control SCC4 cells. Fluorimetric analysis
revealed increased caspase 9 and caspase 3 activities in a
time dependent manner with maximum activity observed
at 36 h of GS treatment (Figure 5A). These results were
further verified by presence of cleaved caspase 9 and cas-
pase 3 using western blotting (Figure 5B). GS treatment
resulted in cleavage of PARP starting from as early as 18
hrs into respective fragments of 116 kDa and 85 kDa with
increased cleavage of PARP by 36 h (Figure 5B). Taken
together, our results demonstrated GS induced apoptosis
by activation of the mitochondrial pathway.
Evaluation of extrinsic pathway/death receptor pathway
in GS-induced apoptosis
In addition to induction of mitochondrial pathway for
apoptosis, we also evaluated expression of Fas/CD95,
truncated Bid (tBid), caspase 8 and its activity. Using flow
cytometric analysis, we observed significant increase in
Fas/CD95 expression (29.5%, p = 0.04) in SCC4 cells
after 36 hrs with GS (Figure 5C). Western blot analysis
showed increased expression of tBid (Figure 3A(vi) and
cleaved caspase 8 (Figure 5B). These results were further
supported by increased caspase 8 activity in GS treated
SCC4 cells (Figure 5A), suggesting involvement of extrin-
sic pathways also in GS induced apoptosis.
Discussion
Abrogation of apoptosis is important for survival and
proliferation of cancer cells. Thus, targeting apoptosis is
considered as an effective therapeutic strategy for treat-
ment of cancer [37,38]. The Bcl2 family of proteins,
including pro-survival members (Bcl2, Bcl-xL and Mcl1)
and pro-apoptotic members (Bax, Bak and Bid) play key
role in integrating apoptotic signals [39]. In addition,
14-3-3 proteins play an important role in regulating the
balance between survival and apoptotic signaling in mul-
tiple ways in cancer cells. Kinases with pro-survival
functions, such as AKT, Rsk and PIM, are responsible
for generating the 14-3-3 docking sites on target pro-
teins [25,30]. The binding of 14-3-3 frequently promotes
re-localization of these pro-apoptotic proteins (Bad, Bax,
FOXO and Ask1) away from their site of action
[25,30-35]. The Bad-14-3-3 interaction causes Bad to be
retained in the cytoplasm, thus, preventing Bad from
dimerizing with Bcl2/xL at the mitochondria and med-
iating the release of Bax from Bcl2/xL-mediated inhibi-
tion [40]. Recently, we reported 14-3-3 zeta
overexpression is associated with development, progres-
sion, poor prognosis and chemo-resistance in head and
neck cancer cells and tissues [26-29]. These findings led
us to propose the natural or chemical inhibitors target-
ing 14-3-3 zeta may serve as potential therapeutic agents
for head and neck cancer.
GS is known anti-proliferative agent for inducing
apoptosis in prostate, lung, colon and head and neck
carcinomas, but the complete mechanism responsible
for induction of apoptosis is unclear. In this study, using
in vitro models of head and neck cancer, we showed 14-
3-3 zeta as a key player regulating apoptosis in GS trea-
ted SCC4 cells. Our co-immunoprecipitation assays
demonstrated that in proliferating, untreated control
SCC4 cells, pBad (Ser 136) is sequestered in cytoplasm
by 14-3-3 zeta, thereby abrogating apoptosis and pro-
moting survival and proliferation. However, treatment
with GS revealed dissociation of Bad from 14-3-3 zeta,
leading to its accumulation on outer mitochondrial
membrane in SCC4 cells. Here, Bad associates with
Bcl2/xL, thereby, releasing Bax to form mitochondrial
permeability transition pores in GS-treated SCC4 cells.
Dissociation of Bad from 14-3-3 zeta and its association
with Bcl2/xL, was verified by reverse immunoprecipita-
tion assays. Further, we showed dissociation of Bad
from 14-3-3 zeta was a result of dephosphorylation of
pBad (Ser 136), a crucial step in decision making for
induction of apoptosis. Interestingly, GS treatment acti-
vated PP2A phosphatases resulting in cytoplasmic accu-
mulation of dephosphorylated Bad in SCC4 cells. In
addition, changes in the Bax/Bcl2 ratio also affect mito-
chondrial membrane potential in cells [39,40]. Our
results of western blotting showed increased Bax/Bcl2
ratio, altering the mitochondrial membrane potential in
GS treated SCC4 cells. This results in leakage of cyto-
chrome c from mitochondria into cytoplasm initiating
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Page 8 of 12Figure 5 (A) GS induces activation of caspases 8/9/3. Quantitative fluorogenic assay for caspase activation was carried out as described in
materials and methods. Treatment with GS (50 μM) induced significant increase in activation of caspases 8/9/3 (*
, ** p < 0.05) in 6 h - 12 h as
compared to vehicle control. (B) Western blot analysis showing (i) cleaved caspase 9; (ii) cleaved caspase 8; (iii) cleaved caspase 3; and (iv)
cleaved PARP confirmed caspase-dependent apoptosis; (iv) a-tubulin served as loading control. (C) GS induced the expression of CD95/Fas.
Panel shows % SCC4 cells expressing CD95/Fas receptor on treatment with GS (50 μM) (i) 0 h; (ii) 6 h; (iii) 12 h; (iv) 24 h; (v) 36 h using flow
cytometry.
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Page 9 of 12apoptosis on treatment with GS. Another noteworthy
observation in our study was significant decrease in
expression of anti-apoptotic proteins, Bcl2, xIAP, Mcl1,
survivin, cyclin D1 and c-myc on treatment with GS in
comparison with no treatment controls, thus commit-
ting cells to apoptosis. These events were followed by
activation of caspase 9 and caspase 3 resulting in clea-
vage of poly (ADP-ribose) polymerase (PARP) in GS
treated SCC4 cells. Taken together, these observations
suggested 14-3-3 zeta plays a key role in GS-induced
apoptosis in head and neck cancer cells as shown in Fig-
ure 6.
Similar to our results, GS treatment has been shown
to alter mitochondrial membrane potential releasing
cytochrome c and initiating apoptosis leukemia, prostate
and colon cancer [15,16,18]. GS also mediates its effects
through downregulation of Akt pathway which pro-
motes survival and proliferation, but activates JNK path-
way inducing apoptosis [13]. In addition, our results
also showed increase in expression of CD95/Fas upon
GS treatment, in a time dependent manner. This
increase in expression of death receptor CD95 coincides
with the activation of caspase-8. GS-treatment increased
expression of truncated Bid (tBid) in SCC4 cells, in a
time dependent manner. Bid is a pro-apoptotic BH3-
only member of the Bcl-2 family and an important com-
ponent of Fas-induced apoptosis [41-43]. Bid is cleaved
by active caspase-8 enhancing cytochrome c release
from mitochondria into the cytosol. Thus, our findings
suggest involvement of both 14-3-3 zeta dependent
Figure 6 The proposed model of GS-mediated apoptosis in HNSCC cells. Our results demonstrated GS targets 14-3-3 zeta to initiate
apoptosis through the intrinsic mitochondrial pathway by releasing Bad from its inhibitory action. Activation of PP2A inhibited association of
Bad with 14-3-3 zeta resulting in its accumulation on outer mitochondrial membrane, altering its membrane potential. This releases cytochrome
c, activating the downstream caspases - caspase 9 and caspase 3. In addition, treatment with GS induces expression of CD95/Fas receptors
leading to caspase 8 activation in head and neck cancer cells.
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Page 10 of 12intrinsic and extrinsic pathway in GS induced apoptosis
(Figure 6).
Conclusion
In conclusion, we demonstrated guggulsterone as an
effective cytotoxic agent inducing apoptosis in head and
neck cancer cells, which are generally chemoresistant.
Further, we showed GS targets 14-3-3 zeta to initiate
apoptosis through intrinsic mitochondrial pathway by
releasing Bad from its inhibitory action. Taken together,
our results provide a biologic rationale for designing
further studies investigating the clinical utility of GS as
a potential complementary therapeutic/chemopreventive
agent for head and neck cancer management.
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